IngredientsSchizochytrium is a genus of unicellular eukaryotes found in coastal marine habitats, assigned to the Stramenopiles (heterokonts), a group that also contains kelp and various microalgae. The full taxonomic classification is: Kingdom: Chromista; Phylum: Bigyra; Class: Labyrinthula; Order: Thraustochytrida; Family: Thraustochytriaceae; Genus: Schizochytrium. It falls under the class Labyrinthulomycetes, which includes microalgae with filamentous growth and ectoplasmic nets for nutrient absorption.
Schizochytrium sp. is a heterotrophic microalga belonging to the order Thraustochytriales within the phylum Heterokonta, which can yield about 40% (w/w) of DHA from its total fatty acid production. Despite frequently being called a "microalga" in commerce and regulatory contexts, thraustochytrids were originally identified as unicellular fungus-like marine protists, later classified into the class Labyrinthulomycetes. They were originally thought to be fungi because of their lack of any photosynthetic machinery, but subsequent molecular biology protocols reclassified them.
The taxonomic classification of the genus Schizochytrium has been subject to revisions. Based on genetic and phenotypic analysis, the genus Schizochytrium was amended and new genera such as Aurantiochytrium and Oblongichytrium were defined. Due to these taxonomical name changes, and for regulatory purposes, the following genus and species are considered included under the umbrella designation Schizochytrium sp.: Schizochytrium aggregatum, Aurantiochytrium limacinum, Aurantiochytrium mangrovei, Oblongichytrium minutum, and Oblongichytrium octosporum. Notable species include Schizochytrium limacinum, often isolated from marine sources like rotted mangrove leaves.
Several stages occur in the lifecycle of Schizochytrium. The feeding form has a stiff, rounded body with cellular extensions used in feeding. Cells can transform into mobile flagellated cells with stiff tripartite hairs typical of the Stramenopiles. Cells can also grow and divide to form a cluster of cells that may become a sorus producing biflagellated zoospores. Certain species produce large amounts of docosahexaenoic acid (DHA) and are grown commercially for production of algae oil for animal feeds, biomass, biofuels, and direct human consumption in supplements and additives.
In commercial and regulatory contexts, Schizochytrium-derived products are most commonly marketed as algal oil, DHA algal oil, or microalgal DHA. The organism has GRAS (Generally Regarded as Safe) status and is commercially known as microalgae or marine algae; it is sold as an animal-free omega-3 ingredient. It appears on product labels variously as Schizochytrium sp. oil, DHA-O, or simply "algal DHA." The standardized regulatory designation used by Australia's Therapeutic Goods Administration is "DHA-rich oil derived from microalgae Schizochytrium sp."
These unicellular, eukaryotic microorganisms are ubiquitous in marine environments, including coastal waters, sediments, and mangrove ecosystems. One commercially important strain, WZU477 (used by Progress Biotech bv), was obtained from a marine environment from rotted mangrove forest leaves. Because Schizochytrium is heterotrophic rather than photosynthetic, it does not require sunlight and can be cultivated entirely in enclosed fermentation vessels on organic carbon substrates β a feature central to its industrial appeal.
There is no documented history of traditional use of Schizochytrium in any human culture. The organism was not identified, used as food, or incorporated into any traditional or folk medicine system prior to modern scientific discovery. All applications of Schizochytrium are products of contemporary biotechnology.
Thraustochytrids were first discovered in 1934, and since the 1960s they have been increasingly studied for their beneficial and deleterious effects. The foundational scientific work of Goldstein and Belsky (1964) first described Schizochytrium as a lipid-rich thraustochytrid, noting its unusual capacity for rapid lipid accumulation. Commercial interest surged in the 1990s when researchers recognized its potential as a sustainable DHA source, leading to patented fermentation processes.
Today, Schizochytrium cultivation supplies food supplements (particularly vegan omega-3 products), aquaculture feed (replacing fishmeal in shrimp and salmon farming), and pharmaceutical applications. In 2019, the global omega-3 market was valued at $2.49 billion and was projected to increase at a compound annual growth rate of 7% by 2027.
Schizochytrium-derived products enter commerce in several distinct forms:
The oil is obtained from microalgae after enzymatic lysis of the cells. An alternative method involves isolation from the microalgae by mechanical extraction.
DHA industrial production is carried out using Schizochytrium limacinum (formerly classified as Aurantiochytrium limacinum) in stirred-tank reactors (STR) or airlift bioreactors. The most commonly used mode of operation is fed-batch, where in the first few days of submerged fermentation, carbon and nitrogen sources are used to stimulate cell growth. High-performing strains β typically from the FCC-3204 lineage β are kept in master cell banks to preserve genetic stability.
Under glucose and nitrogen fed-batch conditions, selected strains have been shown to grow to high biomass densities (100 g/L) in short fermentation cycles (90β100 hours), accumulating 40β45 g/L of DHA, making Schizochytrium the producer of choice in the DHA industry.
DHA constitutes 35β50% of the lipids of Schizochytrium sp. Some strains are capable of accumulating DHA to over 50% of total fatty acids and approximately 50% of the dry cell weight. DHA (docosahexaenoic acid; chemical formula Cββ:βn-3) is a long-chain omega-3 polyunsaturated fatty acid with 22 carbon atoms and six cis-double bonds.
The lipid is primarily in the form of triglycerides (TAGs). Commercial algal oils mainly exist as TAGs (~97%) and contain DHA covering approximately 45% of total fatty acids. The position of omega-3 fatty acids in triglyceride structure is a crucial factor affecting bioavailability, with the sn-2 position having the best enhancing effect. The ratio of sn-2 DHA to total DHA in Schizochytrium sp. was found to be 32β48%, which accounts for high bioavailability of omega-3 fatty acids in the lipid.
Aurantiochytrium and Schizochytrium typically employ the polyketide synthase pathway (PKS pathway) for synthesizing docosapentaenoic acid (DPA, n-6 type) and DHA, accumulating them in lipids by over 60%. DPA (n-6) is present alongside DHA as a co-product of the PKS biosynthetic machinery. Notably, Schizochytrium oil differs from fish oils in its virtual absence of eicosapentaenoic acid (EPA), making it particularly suitable for applications requiring pure DHA supplementation without concurrent EPA intake. However, certain strains and processing conditions may produce both DHA and EPA; one commercially used microalgal oil derived from Schizochytrium sp. contains both DHA and EPA at a ratio of approximately 1:3.
Schizochytrium sp. utilizes both the polyketide synthase complex (PKS) and a single type I fatty acid synthase (FAS) to synthesize polyunsaturated fatty acids and saturated fatty acids, respectively. The main saturated fatty acids produced by the FAS pathway include palmitic acid (16:0) and palmitoleic acid.
Within the cell, large amounts of active substances accumulate, including oil, pigments (carotenoids, lutein, and astaxanthin), and squalene. Thraustochytrids have been explored for their potential in the production of various bioactive compounds such as DHA, carotenoids, and squalene. Squalene is a secondary metabolite of the triterpenoid class with importance in various industrial applications.
The biomass also provides 5β8% dietary fiber, primarily composed of Ξ²-glucans that may confer prebiotic benefits.
Schizochytrium, a member of the Thraustochytrid family, was demonstrated to utilize a polyketide synthase (PKS) pathway as its fatty acid biosynthesis system, similar to that employed by prokaryotes for PUFA biosynthesis. The authors ruled out the existence of a functional membrane-bound desaturase/elongase system for DHA biosynthesis based on the low proportion of desaturase genes identified. The PKS cluster is considered the primary way of PUFA synthesis in Schizochytrium sp. As one of three open reading frames (ORF) in the PKS cluster, ORFC plays an essential role in fatty acid biosynthesis. Similarly to conventional fatty acid synthesis, the biosynthesis of DHA via PKS requires abundant acetyl-CoA and NADPH.
In the brain and retina, DHA is a structural component of neuronal and photoreceptor membranes. Adequate DHA supports normal visual development and cognitive function, particularly during late pregnancy, infancy, and early childhood when brain growth is rapid.
In the cardiovascular system, EPA and DHA modulate triglyceride metabolism, platelet function, and vascular tone. They can reduce hepatic very-low-density lipoprotein (VLDL) production, improve clearance of triglyceride-rich particles, and influence endothelial function.
Clinical investigations of dietary EPA and DHA have demonstrated anti-inflammatory effects of n-3 PUFA supplementation by assessing responses of peripheral blood mononuclear cells (PBMCs). Studies with healthy volunteers showed that omega-3 supplementation reduced the production of cytokines including interleukin-2 (IL-2), interleukin-1 (IL-1), and tumor necrosis factor alpha (TNF-Ξ±).
A randomized, double-blind, placebo-controlled, parallel-group clinical trial analyzed plasma phospholipid levels of 74 adult men and women after 6 and 14 weeks of consuming omega-3 supplements derived from either microalgal or fish oil. The study found that the bioavailability of DHA and EPA in plasma phospholipids from microalgal oil supplements was statistically non-inferior compared to fish oil supplements, indicating that microalgal oil is a reliable and bioavailable source of DHA and EPA.
In this study, a total of 93 healthy adults of ages 21 to 82 were enrolled: 36 in the placebo arm, 37 in the microalgal oil arm, and 20 in the fish oil arm. The study had scientific strengths including its randomized, double-blind, placebo-controlled design and the use of commercially available supplements to ensure real-world relevance.
The EPA and DHA delivered in fish oil and algal oil is largely in the form of triglycerides. By supplying DHA in a triglyceride form similar to that found in human milk, Schizochytrium oil can help bridge dietary gaps for people who consume little or no fish.
Schizochytrium sp. oil is authorised in accordance with European novel food regulations for a number of uses as listed in Commission Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods. In 2021, the EFSA NDA Panel assessed the safety of oil from S. limacinum (strain FCC-3204) and concluded that the ingredient was safe for use in food supplements at the maximum intake level of 1 g DHA/day for adults (excluding pregnant and lactating women) and for use in infant and follow-on formulae. Additional uses for oils obtained from Schizochytrium sp. have been authorised in the EU Union list, including dairy products, fats, fruit and vegetable purees, breakfast cereals, bakery products, and non-alcoholic beverages.
A further EFSA opinion (2024) assessed an extension of use of oil from Schizochytrium limacinum (strain FCC-3204) as a novel food for use as a food ingredient in protein products at a maximum use level of 1 g of DHA in 100 g of product.
One applicant proposed to increase the use level of the novel food as a food supplement, from 250 mg DHA/day (then authorised for the general population, excluding pregnant and lactating women) to 3 g DHA/day for adults. S. limacinum was attributed the Qualified Presumption of Safety (QPS) status by EFSA, with the qualification "for production purposes only."
Aurantiochytrium limacinum (formerly Schizochytrium limacinum) has GRAS (Generally Regarded as Safe) status in the United States, permitting its use in food and feed.
The most robustly studied clinical application of Schizochytrium-derived DHA is its effect on blood lipids. A meta-analysis showed that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease.
While most of the high-dose cardiovascular outcome data come from fish oil studies, the underlying mechanisms are based on the same fatty acids, and algal sources provide a compositionally similar input, particularly when EPA is present.
Evidence strength: Mechanistic evidence for DHA's triglyceride-lowering and vascular effects is supported by multiple studies; the clinical evidence base for DHA specifically from algal Schizochytrium oil in cardiovascular outcomes is still developing relative to the fish-oil literature, and most large cardiovascular outcome trials have used fish oil rather than algal sources.
Evidence suggests a strong association between nutrition during the first 1,000 days (conception to 2 years of life) and cognitive development. Maternal DHA supplementation has been linked with cognitive development of offspring. DHA is a structural component of the human brain and retina and can be derived from marine algae, fatty fish, and marine oils.
A key RCT using algal DHA is the DHANI trial: A double-blind, randomized, placebo-controlled trial among 957 pregnant women in India tested the effectiveness of 400 mg/day algal DHA compared to placebo provided from enrollment (β€20 weeks gestation) through delivery. Among 3,379 women screened, 957 were enrolled and randomized, receiving two microencapsulated algal DHA capsules (200 Γ 2 = 400 mg/day) or placebo daily.
A follow-on to this trial evaluated infant neurodevelopment: A double-blind, randomized, placebo-controlled trial supplemented pregnant Indian women from β€20 weeks through 6 months postpartum with 400 mg/d algal DHA compared to placebo, assessing neurodevelopment of their offspring at 12 months. Of 3,379 women screened, 1,131 were found eligible; 957 were randomized.
EFSA's NDA Panel concluded that DHA should be added to infant and follow-on formulae due to its structural role in the nervous system and the retina and its involvement in normal brain and visual development. The EFSA-established adequate intake (AI) for DHA of 100 mg/day was set for infants and young children between 6 and 24 months, also applied to infants of 0β6 months, taking into account the concentration of essential fatty acids including DHA in human breast milk.
DHA appears to be safe, with no adverse birth outcomes related to DHA supplementation observed in low-risk pregnancy cases.
Evidence strength: Several large, well-designed RCTs have used algal DHA specifically in pregnant populations, making the evidence for safety in pregnancy reasonably robust. Evidence for efficacy in improving neurodevelopmental outcomes in offspring is mixed across trials; results depend on baseline DHA status, population, and dose. EFSA's mandatory addition of DHA to infant formula reflects institutional confidence in the mechanistic and nutritional evidence.
The DHA-rich oil derived from Schizochytrium is obtained from microalgae after enzymatic lysis. Applicants have proposed its use in infant formulae (IF) and follow-on formulae (FOF). The use level was derived from EU Regulation 2016/127, which mandates the addition of DHA to IF and FOF at the level of 20β50 mg/100 kcal. The intake of DHA resulting from this use is not expected to pose safety concerns.
The strain TKD-1, belonging to the species Schizochytrium limacinum, produces a novel food that is a mixture of triglycerides in which DHA represents 53β61% of fatty acids, for use in infant and follow-on formulae.
Evidence strength: Multiple EFSA novel food safety opinions have assessed individual Schizochytrium strains for infant formula use. Safety is generally supported. Efficacy data supporting specific health outcomes in infants from algal DHA in formula is extrapolated partly from mechanistic data on DHA's structural role.
Whole cell Schizochytrium sp. is a rich source of omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) including DHA, an important nutrient for brain health. In a canine study of senescence, aged beagle dogs were assessed on a visuospatial task of working memory; DHA wt% of total phospholipids and 8-iso-PGF2Ξ± concentrations in plasma were used to assess the efficacy of DHA-rich microalgae after 25 weeks on a fortified diet.
Evidence strength: Most mechanistic evidence for DHA's role in cognition and visual function in humans is indirect or extrapolated from infant/developmental studies. Direct human RCTs using Schizochytrium-derived DHA specifically for cognitive enhancement in healthy adults are limited. Evidence for visual acuity benefits comes predominantly from infant and developmental study contexts.
Dietary n-3 polyunsaturated fatty acids have demonstrated health benefits for a wide range of diseases in both preclinical and clinical studies, particularly for conditions with underlying chronic inflammation such as cardiovascular disease, rheumatoid arthritis, dementia, and cancer. In a study of older adults, treatment with 1.8 g/day EPA+DHA for six months resulted in PBMCs with decreased pro-inflammatory gene expression involving the interleukin, MAP kinase, NF-ΞΊB, and Toll-like receptor signaling pathways.
Evidence strength: Anti-inflammatory effects of omega-3 PUFAs including DHA are well-supported at a mechanistic level. However, most human trials with demonstrated immunomodulatory effects used fish oil containing both EPA and DHA. Evidence specifically isolating the contribution of Schizochytrium-derived DHA to clinical inflammatory outcomes in humans is preliminary and largely extrapolated from the broader omega-3 literature.
Algal oil is also used for improving thinking skills, physical performance, autism, ADHD, and depression, but there is no good scientific evidence to support these uses. These applications are based on the general biology of DHA but have not been validated in rigorous human trials using Schizochytrium-derived oil as the intervention.
The following dosages are reported in specific studies or regulatory opinions cited above, and are not general recommendations:
A battery of comprehensive genetic toxicity tests was conducted to evaluate the safety of DHA-rich Algal Oil from Schizochytrium sp. Potential genotoxicity was investigated using a bacterial reverse mutation assay (Ames test), a chromosome aberration test in human lymphocytes, and an in vivo micronucleus test in mouse immature erythrocytes. The results of all genotoxicity tests were negative.
Toxicity testing included a 90-day study preceded by a 4-week pretreatment period of parental rats, with exposure of the dams throughout mating, gestation, and lactation β a design used to mimic the intended exposure of pregnant women and infants to the oil. There were no treatment-related effects of DHA-rich Algal Oil on clinical observations, body weight, food consumption, behavior, hematology, clinical chemistry, coagulation, or urinalysis.
Increases in absolute and relative weights of the liver, kidney, spleen, and adrenals (adrenals and spleen with histological correlates) were observed in both the fish oil- and the high-dose DHA-rich Algal Oil-treated female animals. This finding, observed in both algal oil and the fish oil control group at high doses, was not considered a unique adverse effect of the algal oil specifically.
The intake of DHA resulting from the use of Schizochytrium sp. oil in infant and follow-on formulae at the levels defined by EU regulation is not expected to pose safety concerns. This conclusion was reiterated in a separate EFSA opinion on a different strain.
For one strain (Schizochytrium sp. ATCC 20889), due to incomplete species-level characterization and absence of strain-specific toxicological data, EFSA concluded that the safety of that particular novel food had not been established. This illustrates that regulatory safety opinions are strain-specific and cannot be universally applied across all Schizochytrium strains.
A key safety advantage of Schizochytrium oil relative to fish oil is the closed, controlled fermentation environment. Marine biotoxins (including cyanotoxins) in EFSA-assessed novel food preparations were below their limits of quantification. Recent advances in molecular distillation techniques have enabled production of food-grade oils with undetectable levels of environmental contaminants, addressing a significant limitation of traditional marine-sourced omega-3 products.
Algal oil supplements are well tolerated, with adverse effects typically mild and infrequent. The most commonly reported side effects include mild gastrointestinal symptoms such as nausea, bloating, or loose stools, and a fishy or seaweed-like aftertaste or burping (less common than with fish oil). Allergic reactions are rare but possible in individuals sensitive to algae.
Omega-3 fatty acids possess mild antiplatelet effects, which may theoretically increase bleeding risk when combined with anticoagulant medications such as warfarin, or antiplatelet drugs like clopidogrel or aspirin. If taking warfarin, monitoring of INR is advisable when starting omega-3 supplements.
DHA might lower blood pressure. Taking it alongside other supplements that have the same effect might cause blood pressure to drop too much.
Clinically significant interactions are uncommon at standard supplemental doses.
Single-cell oils from microalgae possess remarkable oxidative and flavor stability. Schizochytrium sp. oil under frozen conditions showed only a minor change over 2 years. This stability is a practical safety and quality consideration, as oxidized omega-3 products may have altered safety and efficacy profiles.
Health conditions that Schizochytrium may help support.
Body systems that Schizochytrium may help support.
Go back